Dr Roger Aston currently serves as Executive Chairman of PharmAust. Dr Aston brings more than 20 years experience in the pharmaceutical and healthcare industries in senior roles in the UK, Asia Pacific and Australia. He has had extensive experience on boards and as Chief Executive Officer of many private and publicly listed biotechnology companies. During his career, he has been closely involved in start-up companies and major pharmaceutical companies. Aspects of his experience include FDA and EU product registration, clinical trials, global licensing agreements, fundraising through private placements, and a network of contacts within the pharmaceutical, banking and stock broking sectors. Dr Aston holds a B.Sc. (Hons) and Ph.D. degrees from the University of Manchester from 1975 to 1981.
Connect with Roger:
PharmAust Ltd, a clinical-stage biotechnology company, is pleased to announce positive top-line data from its Phase 2 veterinary clinical study of monepantel (MPL) for treating Canine B-Cell Lymphoma. Data...
Biotech company PharmAust Limited is pleased to announce a significant milestone for a four-legged patient in the Phase 2 trial for the treatment of canine B-cell Lymphoma. Thirteen-year-old Beagle ‘Louie’...
A retired policeman’s quest to improve his dog’s quantity and quality of life As a pet owner, hearing the news that your furry companion has been diagnosed with cancer can be devastating. Retired Melbourne...
PharmAust is continuing the recruitment of pet dogs in Australia, New Zealand and the United States with untreated B cell lymphoma to finalise the evaluation of a promising, newly formulated anti-cancer...
PharmAust is continuing the recruitment of pet dogs in Australia, New Zealand and the United States with untreated B cell lymphoma to finalise the evaluation of a promising, newly formulated anti-cancer...
PharmAust is a clinical-stage company developing therapeutics for humans & animals. They specialise in repurposing marketed drugs, lowering the risks and costs of development. 1. They are absolute experts at … helping treat dogs with aggressive lymphoma
And a timely reminder for your veterinary clients to check their dog for lumps and bumps On a mission to find a treatment for canine lymphoma, biotech company PharmAust is reminding dog owners to check...
PharmAust is calling for pet dogs with B cell lymphoma for the next clinical phase of promising anti-cancer trial running in Australia, New Zealand and now the USA Biotech company PharmAust is...
PharmAust Commences Next Clinical Phase of Monepantel Anti-Cancer Trial for Pet Dogs in New Zealand – MPL treatment stabilises B cell lymphoma,can make lesions disappear Significantly prolongs life and provides excellent quality of life of trial pet dogs
Great success has been achieved by PharmAust in its clinical trials testing the drug monepantel as an anticancer agent for pet dogs with treatment naive B cell lymphoma. PharmAust has made monepantel into a convenient, take at home tablet.
